Utilization of autologous superficial femoral vein graft in
cases of infected prosthetic graft replacement and high
infection-risk cases

k 2019

Utilization of autologous superficial femoral vein graft in cases of infected prosthetic graft replacement and high infection-risk cases

KUBÍČEK, Luboš; Robert STAFFA; Zdeněk KŘÍŽ; Tomáš NOVOTNÝ; Robert VLACHOVSKÝ et. al.

Základní údaje

Originální název

Utilization of autologous superficial femoral vein graft in cases of infected prosthetic graft replacement and high infection-risk cases

Autoři

KUBÍČEK, Luboš (203 Česká republika, domácí); Robert STAFFA (203 Česká republika, garant, domácí); Zdeněk KŘÍŽ (203 Česká republika); Tomáš NOVOTNÝ (203 Česká republika, domácí) a Robert VLACHOVSKÝ (203 Česká republika, domácí)

Vydání

33rd ESVS Annual Meeting 2019, 2019

Další údaje

Jazyk

angličtina

Typ výsledku

Prezentace na konferencích

Obor

30212 Surgery

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14110/19:00108562

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

autologous superficial femoral vein graft; acute mesenteric ischemia; biomarkers

Štítky

rivok

Změněno: 10. 1. 2020 12:48, MUDr. Tomáš Novotný, Ph.D.

Anotace

V originále

Introduction: Aortic prosthetic graft infection is one of the most severe complications in vascular surgery. Good results are reported for the replacement using autologous superficial femoral vein (SFV) graft. This extensive procedure might be complicated by acute mesenteric ischemia (AMI). The aim of the study was to evaluate the safety of the procedure and options of early postoperative mesenteric ischemia detection. Methods: A retrospective review of 64 cases in which we have used autologous SFV graft was performed. The serum levels of biomarkers of AMI were assessed in comparison to 40 elective aortic surgery cases. Results: Average follow-up was 46.6 +/- 33.0 months, 30-day mortality was 6.3 %. The specificity of currently studied biomarkers of AMI (procalcitonin, ischemia modified albumin, I-FAPB2, and D-lactate) was low. Conclusions: Our results support the use of SFV graft for the treatment of aortic graft infection. Early postoperative detection of AMI remains challenging.

Návaznosti

NV17-29701A, projekt VaV

Název: Ischémií modifikovaný albumin a cirkulující mikroRNA jako nové technologie k monitorování tkáňové ischémie po cévních rekonstrukcích na břišní aortě

Citovat

KUBÍČEK, Luboš; Robert STAFFA; Zdeněk KŘÍŽ; Tomáš NOVOTNÝ a Robert VLACHOVSKÝ. Utilization of autologous superficial femoral vein graft in cases of infected prosthetic graft replacement and high infection-risk cases. In 33rd ESVS Annual Meeting 2019. 2019.

@proceedings{1601633,
   author = {Kubíček, Luboš and Staffa, Robert and Kříž, Zdeněk and Novotný, Tomáš and Vlachovský, Robert},
   booktitle = {33rd ESVS Annual Meeting 2019},
   keywords = {autologous superficial femoral vein graft; acute mesenteric ischemia; biomarkers},
   language = {eng},
   title = {Utilization of autologous superficial femoral vein graft in cases of infected prosthetic graft replacement and high infection-risk cases},
   year = {2019}
}

TY  - CONF
ID  - 1601633
AU  - Kubíček, Luboš - Staffa, Robert - Kříž, Zdeněk - Novotný, Tomáš - Vlachovský, Robert
PY  - 2019
TI  - Utilization of autologous superficial femoral vein graft in cases of infected prosthetic graft replacement and high infection-risk cases
KW  - autologous superficial femoral vein graft
KW  - acute mesenteric ischemia
KW  - biomarkers
N2  - Introduction: Aortic prosthetic graft infection is one of the most severe complications in vascular surgery. Good results are reported for the replacement using autologous superficial femoral vein (SFV) graft. This extensive procedure might be complicated by acute mesenteric ischemia (AMI). The aim of the study was to evaluate the safety of the procedure and options of early postoperative mesenteric ischemia detection. Methods: A retrospective review of 64 cases in which we have used autologous SFV graft was performed. The serum levels of biomarkers of AMI were assessed in comparison to 40 elective aortic surgery cases. Results: Average follow-up was 46.6 +/- 33.0 months, 30-day mortality was 6.3 %. The specificity of currently studied biomarkers of AMI (procalcitonin, ischemia modified albumin, I-FAPB2, and D-lactate) was low. Conclusions: Our results support the use of SFV graft for the treatment of aortic graft infection. Early postoperative detection of AMI remains challenging.
ER  -

Přehled o publikaci